GbS Global Biopharma Inc.

GbS Global Biopharma ("GbS"), the wholly-owned Canadian subsidiary of GB Sciences, Inc. (OTCQB:GBLX), is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform plant-inspired drug development targeting novel treatments for multi-billion dollar biopharma markets. GbS’ proprietary Generative-AI Powered Drug Discovery Platform (PhAROS™) predicts novel, simple, plant-based mixtures to address multi-billion-dollar markets. PhAROS™ leverages demonstrated healing from within 12 global Traditional Medical Systems (TMS); pre-validates novel, simple, plant-based mixtures to address multi-billion-dollar markets; and goes beyond looking at what has worked within plant-based medicines in the past to predicting the efficacies of entirely new formulations that have not existed anywhere. GbS’ new proprietary mixtures often include components from different plants growing on different continents in different TMS that may never have been used together before. GbS' novel AI-powered drug discovery platform has yielded 8 US & 14 global patents that are issued and protect 28 unique formulas for human health disorders. Additionally, GbS has 15 US and 41 global patents-pending that cover 25 unique formulas for human health disorders. GbS has 5 late preclinical programs with cell & animal data supporting novel treatments of Parkinson’s disease, chronic pain, stress & anxiety, cytokine syndromes, and heart failure. Our lead Parkinson’s disease therapeutic program is being prepared for a First-in-Man clinical trial. GbS' productive research and development network includes industry leading biopharmaceutical CMOs, service providers, universities, hospitals, and global clinical CROs.